A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qian, Xiong, Yiting, Zhang, Shujuan, Chen, Xinling, Yi, Fengming, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960125/
https://www.ncbi.nlm.nih.gov/pubmed/31970086
http://dx.doi.org/10.3389/fonc.2019.01460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960125/
https://www.ncbi.nlm.nih.gov/pubmed/31970086
http://dx.doi.org/10.3389/fonc.2019.01460

Ejemplares similares